Retreatment with Sofosbuvir/Velpatasvir/Voxilaprevir for 12 weeks is safe and effective for patients who have previously received Sofosbuvir/Velpatasvir or Sofosbuvir/ Velpatasvir/Voxilaprevir

导出原文传递

翻译打印收藏纠错

作者： Ruane, P. ^[1] ; Strasser, S. J. ^[2] ; Gane, E. J. ^[3] ; Hyland, R. H. ^[4] ; Shao, J. ^[5] ; Dvory-Sobol, H. ^[6] ; Tran, T. ; Stamm, L. M. ; Brainard, D. M. ; Nyberg, L. ; Shafran, S.

作者单位： AW Morrow Gastroenterol & Liver Ctr, Sydney, Australia ^[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA ^[2] Kaiser Permanente, San Diego, CA USA ^[3] Ruane Med & Liver Hlth Inst, Los Angeles, CA USA ^[4] Univ Alberta, Edmonton, AB, Canada ^[5] Univ Auckland, Auckland, New Zealand ^[6]

发布时间 2021-01-15

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Journal of viral hepatitis.

2018年25卷S2期

193-193页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Retreatment with Sofosbuvir/Velpatasvir/Voxilaprevir for 12 weeks is safe and effective for patients who have previously received Sofosbuvir/Velpatasvir or Sofosbuvir/ Velpatasvir/Voxilaprevir

Journal of viral hepatitis.

相似文献

Journal of viral hepatitis.

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Retreatment with Sofosbuvir/Velpatasvir/Voxilaprevir for 12 weeks is safe and effective for patients who have previously received Sofosbuvir/Velpatasvir or Sofosbuvir/ Velpatasvir/Voxilaprevir

Journal of viral hepatitis.

相似文献

Journal of viral hepatitis.

相关期刊

检索历史清除